68 related articles for article (PubMed ID: 21421039)
1. Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion.
Su M; Zhao M; Luo Y; Lin X; Xu L; He H; Xu H; Tang X
Int J Pharm; 2011 Jun; 411(1-2):188-96. PubMed ID: 21421039
[TBL] [Abstract][Full Text] [Related]
2. Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique.
Li Y; Jin W; Yan H; Liu H; Wang C
Int J Pharm; 2013 Sep; 454(1):472-7. PubMed ID: 23806812
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
4. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
7. [Characterization of vinflunine tartrate liposomes in vitro and in vivo].
Zou WW; Wang DH; Sun CY; Han JB; Yin Q; Yang QM; Wang JY
Yao Xue Xue Bao; 2011 Dec; 46(12):1515-9. PubMed ID: 22375428
[TBL] [Abstract][Full Text] [Related]
8. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
9. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics.
Zhang HY; Tang X; Li HY; Liu XL
Int J Pharm; 2008 Feb; 348(1-2):70-9. PubMed ID: 17719191
[TBL] [Abstract][Full Text] [Related]
10. The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer.
Ferrero JM; Chamorey E; Magné N; Leccia F; Largillier R; Namer M; Milano G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):459-64. PubMed ID: 12451472
[TBL] [Abstract][Full Text] [Related]
11. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
[TBL] [Abstract][Full Text] [Related]
13. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.
Brogden JM; Nevidjon B
Oncol Nurs Forum; 1995 May; 22(4):635-46. PubMed ID: 7675666
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
17. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Pieńkowski T; Jagiello-Gruszfeld A
Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
[TBL] [Abstract][Full Text] [Related]
18. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluations of norcantharidin-loaded intravenous lipid microspheres with low toxicity.
Lin X; Zhang B; Zhang K; Zhang Y; Wang J; Qi N; Yang S; He H; Tang X
Expert Opin Drug Deliv; 2012 Dec; 9(12):1449-62. PubMed ID: 22971185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]